Silence Therapeutics is a pioneer in the discovery, design and development of siRNA (short interfering RNA) therapies. Our proprietary mRNAi GOLD™ platform can be used to create siRNAs for both common and rare genetic diseases. SLN360 is our wholly owned siRNA in phase 2 development (the ALPACAR-360 trial) for the treatment of high lipoprotein(a), a key genetic risk factor for cardiovascular disease impacting up to 20% of the world's population. Results from the APOLLO phase 1 single dose study of SLN360 in healthy volunteers with high Lp(a) were simultaneously presented at ACC 2022 and published in JAMA. For more information about our pipeline and collaborations, please visit https://www.silence-therapeutics.com/.
Additional Info
We will be displaying a new product or promoting a new indication/enhanced feature for an existing product in our booth!
NoFirst time Exhibitor?
Yes